{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:23Z","timestamp":1792612283866,"version":"4.5.0"},"reference-count":279,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.lfs.2023.121803","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:07:54Z","timestamp":1685099274000},"page":"121803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine"],"prefix":"10.1016","volume":"326","author":[{"given":"Miroslav","family":"Adzic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Mitic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilija","family":"Glavonic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dragicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Ivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7526","key":"10.1016\/j.lfs.2023.121803_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/515180a","article-title":"Mental health: a world of depression","volume":"515","author":"Smith","year":"2014","journal-title":"Nature"},{"issue":"Suppl E1","key":"10.1016\/j.lfs.2023.121803_bb0010","first-page":"4","article-title":"Relationship of neurotransmitters to the symptoms of major depressive disorder","volume":"69","author":"Nutt","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0015","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/mp.2017.36","article-title":"Identifying fast-onset antidepressants using rodent models","volume":"22","author":"Ramaker","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0025","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41380-021-01381-x","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","volume":"27","author":"Sforzini","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11606-006-0101-4","article-title":"Prevalence of depression-PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions","volume":"22","author":"Campbell","year":"2007","journal-title":"J. Gen. Intern. Med."},{"issue":"14","key":"10.1016\/j.lfs.2023.121803_bb0035","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2174\/138161209788168100","article-title":"Opiates as antidepressants","volume":"15","author":"Berrocoso","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","article-title":"Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches","volume":"24","author":"Pecina","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/HRP.0000000000000242","article-title":"Novel targets to treat depression: opioid-based therapeutics","volume":"28","author":"Browne","year":"2020","journal-title":"Harv. Rev. Psychiatry"},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11055-007-0029-0","article-title":"Coaxil (tianeptine) in the treatment of depression in Parkinson\u2019s disease","volume":"37","author":"Levin","year":"2007","journal-title":"Neurosci. Behav. Physiol."},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb0055","first-page":"24","article-title":"Efficacy and tolerability of coaxil (tianeptine) in the therapy of posttraumatic stress disorder","volume":"105","author":"Aleksandrovskii","year":"2005","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11055-008-9099-x","article-title":"Use of Coaxil (tianeptine) in elderly patients with combined mild cognitive and depressive-anxiety disorders","volume":"39","author":"Karpukhin","year":"2009","journal-title":"Neurosci. Behav. Physiol."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0065","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0075","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0306-4522(98)00251-6","article-title":"Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study","volume":"88","author":"Peckys","year":"1999","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2012.01.013","article-title":"Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR","volume":"124","author":"Peng","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.lfs.2023.121803_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/0261192920939876","article-title":"Some reasons why preclinical studies of psychiatric disorders fail to translate: what can be rescued from the misunderstanding and misuse of animal \u2018models\u2019?","volume":"48","author":"Stanford","year":"2020","journal-title":"Altern. Lab. Anim. ATLA"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/bjaceaccp\/mku041","article-title":"Opioid receptors","volume":"15","author":"McDonald","year":"2014","journal-title":"BJA Education"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0100","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0026-895X(24)23045-5","article-title":"Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization","volume":"60","author":"Chavkin","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/bbrc.1997.7242","article-title":"Carboxyl terminus of delta opioid receptor is required for agonist-dependent receptor phosphorylation","volume":"238","author":"Zhao","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0115","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12560","article-title":"Opioids in cancer: the kappa-opioid receptor (review)","volume":"25","author":"Zhou","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2023.121803_bb0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fncel.2014.00186","article-title":"Kir3 channel signaling complexes: focus on opioid receptor signaling","volume":"8","author":"Nagi","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"17","key":"10.1016\/j.lfs.2023.121803_bb0125","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1523\/JNEUROSCI.17-17-06565.1997","article-title":"Kappa-opioid receptor activation modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals","volume":"17","author":"Rusin","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2023.121803_bb0130","first-page":"53","article-title":"Opioid receptor coupling to GIRK channels. In vitro studies using a Xenopus oocyte expression system and in vivo studies on weaver mutant mice","volume":"84","author":"Ikeda","year":"2003","journal-title":"Methods Mol. Med."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FJC.0000000000000482","article-title":"G protein-coupled receptor signaling through beta-arrestin-dependent mechanisms","volume":"70","author":"Jean-Charles","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"10","key":"10.1016\/j.lfs.2023.121803_bb0140","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1139\/y96-124","article-title":"G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins","volume":"74","author":"Ferguson","year":"1996","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"30","key":"10.1016\/j.lfs.2023.121803_bb0145","doi-asserted-by":"crossref","first-page":"27662","DOI":"10.1074\/jbc.M502593200","article-title":"Mu and kappa opioid receptors activate ERK\/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes","volume":"280","author":"Belcheva","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.lfs.2023.121803_bb0150","doi-asserted-by":"crossref","first-page":"15281","DOI":"10.1073\/pnas.2000500117","article-title":"Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain","volume":"117","author":"Jimenez-Vargas","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb0155","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cellsig.2008.09.002","article-title":"Delta-opioid receptors activate ERK\/MAP kinase via integrin-stimulated receptor tyrosine kinases","volume":"20","author":"Eisinger","year":"2008","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1471-4159.2004.02338.x","article-title":"Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptor-induced activation of c-Jun N-terminal kinase","volume":"89","author":"Kam","year":"2004","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/jpet.105.091447","article-title":"delta opioid receptors stimulate Akt-dependent phosphorylation of c-jun in T cells","volume":"316","author":"Shahabi","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"26","key":"10.1016\/j.lfs.2023.121803_bb0170","doi-asserted-by":"crossref","first-page":"18081","DOI":"10.1074\/jbc.M513640200","article-title":"Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes","volume":"281","author":"Bruchas","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.lfs.2023.121803_bb0175","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1074\/jbc.M806742200","article-title":"p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons","volume":"284","author":"Tan","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0180","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1046\/j.1471-4159.1999.0731502.x","article-title":"Endogenous delta-opioid and ORL1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C","volume":"73","author":"Zhang","year":"1999","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","article-title":"Kinase cascades and ligand-directed signaling at the kappa opioid receptor","volume":"210","author":"Bruchas","year":"2010","journal-title":"Psychopharmacology."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1124\/mol.110.066613","article-title":"mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization","volume":"78","author":"McPherson","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"7711","key":"10.1016\/j.lfs.2023.121803_bb0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the micro-opioid receptor-G(i) protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"issue":"Pt 5","key":"10.1016\/j.lfs.2023.121803_bb0200","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/awm255","article-title":"Imaging of opioid receptors in the central nervous system","volume":"131","author":"Henriksen","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1213\/01.ane.0000221457.71536.e0","article-title":"Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers","volume":"103","author":"Becerra","year":"2006","journal-title":"Anesth. Analg."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0210","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/S1461145711001842","article-title":"Active behaviours produced by antidepressants and opioids in the mouse tail suspension test","volume":"16","author":"Berrocoso","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0220","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1017\/S1461145709000236","article-title":"Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression","volume":"12","author":"Berrocoso","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0225","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbr.2014.10.014","article-title":"Antidepressant-like effects of buprenorphine in rats are strain dependent","volume":"278","author":"Browne","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0024-3205(02)02220-8","article-title":"Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats","volume":"72","author":"Rojas-Corrales","year":"2002","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0235","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00213-014-3723-y","article-title":"Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice","volume":"232","author":"Falcon","year":"2015","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/76061","article-title":"Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses","volume":"25","author":"Filliol","year":"2000","journal-title":"Nat. Genet."},{"issue":"14","key":"10.1016\/j.lfs.2023.121803_bb0245","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1111\/bph.13808","article-title":"mu opioid receptor, social behaviour and autism spectrum disorder: reward matters","volume":"175","author":"Pellissier","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.pbr.2018.07.009","article-title":"Potential roles for opioid receptors in motivation and major depressive disorder","volume":"239","author":"Callaghan","year":"2018","journal-title":"Prog. Brain Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/syn.10146","article-title":"Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats","volume":"46","author":"Robinson","year":"2002","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0260","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hipo.20161","article-title":"Opiates, psychostimulants, and adult hippocampal neurogenesis: insights for addiction and stem cell biology","volume":"16","author":"Eisch","year":"2006","journal-title":"Hippocampus"},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0265","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1460-9568.2006.04621.x","article-title":"Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects","volume":"23","author":"Zhang","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb0270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/cns.12409","article-title":"Modulation of mTOR activity by mu-opioid receptor is dependent upon the association of receptor and FK506-binding protein 12","volume":"21","author":"Wang","year":"2015","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0275","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI70236","article-title":"Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia","volume":"124","author":"Xu","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0280","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/jpet.102.038133","article-title":"GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system","volume":"303","author":"Tao","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2023.121803_bb0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0079-6123(08)00912-6","article-title":"The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer\u2019s disease","volume":"172","author":"Michelsen","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"6649","key":"10.1016\/j.lfs.2023.121803_bb0290","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/38730","article-title":"Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor","volume":"389","author":"Pan","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0295","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","article-title":"Opioids excite dopamine neurons by hyperpolarization of local interneurons","volume":"12","author":"Johnson","year":"1992","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0300","first-page":"1236","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/syn.20122","article-title":"Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA\/2J and C57BL\/6J mice","volume":"56","author":"Fadda","year":"2005","journal-title":"Synapse"},{"issue":"39","key":"10.1016\/j.lfs.2023.121803_bb0310","doi-asserted-by":"crossref","first-page":"16446","DOI":"10.1073\/pnas.1105418108","article-title":"Neuronal circuits underlying acute morphine action on dopamine neurons","volume":"108","author":"Jalabert","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2023.121803_bb0315","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neubiorev.2019.10.015","article-title":"Stress-induced plasticity and functioning of ventral tegmental dopamine neurons","volume":"108","author":"Douma","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0320","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02246283","article-title":"Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats","volume":"123","author":"Besson","year":"1996","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2023.121803_bb0325","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0006-8993(95)00333-L","article-title":"Increased density of mu-opioid receptors in the postmortem brain of suicide victims","volume":"682","author":"Gabilondo","year":"1995","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0330","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/sj.npp.1300459","article-title":"Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims","volume":"29","author":"Escriba","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0335","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41386-021-00974-y","article-title":"Increased functional coupling of the mu opioid receptor in the anterior insula of depressed individuals","volume":"46","author":"Lutz","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb0340","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/archpsyc.63.11.1199","article-title":"Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women","volume":"63","author":"Kennedy","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb0345","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41386-020-0725-9","article-title":"Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety","volume":"45","author":"Nummenmaa","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0350","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","article-title":"The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor","volume":"103","author":"Kroslak","year":"2007","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0355","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/17470919.2010.482786","article-title":"Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients","volume":"6","author":"Troisi","year":"2011","journal-title":"Soc. Neurosci."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0360","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","article-title":"The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system","volume":"28","author":"Land","year":"2008","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0365","first-page":"7","article-title":"U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist","volume":"224","author":"Vonvoigtlander","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4765","key":"10.1016\/j.lfs.2023.121803_bb0370","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.lfs.2023.121803_bb0375","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2023.121803_bb0380","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","article-title":"Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders","volume":"60","author":"Jacobson","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"41","key":"10.1016\/j.lfs.2023.121803_bb0385","doi-asserted-by":"crossref","first-page":"29803","DOI":"10.1074\/jbc.M705540200","article-title":"Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase","volume":"282","author":"Bruchas","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.lfs.2023.121803_bb0390","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1073\/pnas.1205565109","article-title":"Stress-induced epigenetic regulation of kappa-opioid receptor gene involves transcription factor c-Myc","volume":"109","author":"Flaisher-Grinberg","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2023.121803_bb0395","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2023.121803_bb0400","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neubiorev.2019.12.007","article-title":"Opioid receptor modulation of neural circuits in depression: what can be learned from preclinical data?","volume":"108","author":"Puryear","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0405","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpsychires.2008.01.018","article-title":"Role of extracellular signal-regulated kinase signal transduction pathway in anxiety","volume":"43","author":"Ailing","year":"2008","journal-title":"J. Psychiatr. Res."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0410","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1017\/S1461145711000897","article-title":"Regionally selective activation and differential regulation of ERK, JNK and p38 MAP kinase signalling pathway by protein kinase C in mood modulation","volume":"15","author":"Galeotti","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0415","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/BPL-170062","article-title":"JNK regulation of depression and anxiety","volume":"3","author":"Hollos","year":"2018","journal-title":"Brain Plast."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb0420","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1007\/s12035-019-1524-3","article-title":"The ERK pathway: molecular mechanisms and treatment of depression","volume":"56","author":"Wang","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0425","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1152\/physrev.00017.2008","article-title":"Transcription factors in long-term memory and synaptic plasticity","volume":"89","author":"Alberini","year":"2009","journal-title":"Physiol. Rev."},{"issue":"15","key":"10.1016\/j.lfs.2023.121803_bb0430","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1093\/emboj\/17.15.4426","article-title":"Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2\/p38, and may mediate activation of CREB","volume":"17","author":"Deak","year":"1998","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0435","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci."},{"issue":"18","key":"10.1016\/j.lfs.2023.121803_bb0440","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1523\/JNEUROSCI.21-18-07397.2001","article-title":"Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens","volume":"21","author":"Pliakas","year":"2001","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0445","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/bcp.12845","article-title":"New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs","volume":"82","author":"Ignacio","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0450","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fncel.2020.00082","article-title":"The role of BDNF on neural plasticity in depression","volume":"14","author":"Yang","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.lfs.2023.121803_bb0455","doi-asserted-by":"crossref","first-page":"33401","DOI":"10.1038\/srep33401","article-title":"Chronic Kappa opioid receptor activation modulates NR2B: implication in treatment resistant depression","volume":"6","author":"Dogra","year":"2016","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.lfs.2023.121803_bb0460","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses","volume":"23","author":"McLaughlin","year":"2003","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0465","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.npp.1300872","article-title":"Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"36","key":"10.1016\/j.lfs.2023.121803_bb0470","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1523\/JNEUROSCI.2053-12.2012","article-title":"Repeated stress dysregulates kappa-opioid receptor signaling in the dorsal raphe through a p38alpha MAPK-dependent mechanism","volume":"32","author":"Lemos","year":"2012","journal-title":"J. Neurosci."},{"issue":"24","key":"10.1016\/j.lfs.2023.121803_bb0475","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1523\/JNEUROSCI.21-24-09917.2001","article-title":"Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors","volume":"21","author":"Celada","year":"2001","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0480","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1152\/jn.00855.2004","article-title":"Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons","volume":"93","author":"Margolis","year":"2005","journal-title":"J. Neurophysiol."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0485","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10571-012-9827-1","article-title":"Stress-related serotonergic systems: implications for symptomatology of anxiety and affective disorders","volume":"32","author":"Hale","year":"2012","journal-title":"Cell. Mol. Neurobiol."},{"issue":"13","key":"10.1016\/j.lfs.2023.121803_bb0490","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2013.171","article-title":"Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion","volume":"38","author":"Chefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"0 0","key":"10.1016\/j.lfs.2023.121803_bb0495","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuropharm.2013.05.024","article-title":"Addiction as a stress surfeit disorder","volume":"76 Pt B","author":"Koob","year":"2014","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0500","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.lfs.2023.121803_bb0505","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress. Anxiety"},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb0510","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamapsychiatry.2014.1221","article-title":"Association of in vivo kappa-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology","volume":"71","author":"Pietrzak","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb0515","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1172\/JCI70395","article-title":"Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression","volume":"123","author":"Anderson","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0520","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.mp.4000930","article-title":"Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex","volume":"7","author":"Hurd","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.lfs.2023.121803_bb0525","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.biopsych.2017.07.012","article-title":"Epigenetic regulation of the kappa opioid receptor by child abuse","volume":"84","author":"Lutz","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0530","doi-asserted-by":"crossref","first-page":"E704","DOI":"10.1208\/aapsj070371","article-title":"Kappa opioid antagonists: past successes and future prospects","volume":"7","author":"Metcalf","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.lfs.2023.121803_bb0535","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2210-12-5","article-title":"Long-acting kappa opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity","volume":"12","author":"Munro","year":"2012","journal-title":"BMC Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0540","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0545","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0550","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/npp.2009.183","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats","volume":"35","author":"Carr","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0555","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1037\/bne0000215","article-title":"Strain-dependent sex differences in a long-term forced swim paradigm","volume":"131","author":"Colom-Lapetina","year":"2017","journal-title":"Behav. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.121803_bb0560","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2007.05.045","article-title":"Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies","volume":"570","author":"Zhang","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0565","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fphar.2018.00093","article-title":"Sex differences in the effects of a kappa opioid receptor antagonist in the forced swim test","volume":"9","author":"Laman-Maharg","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0570","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.biopha.2018.10.144","article-title":"Involvement of opioid system in behavioral despair induced by social isolation stress in mice","volume":"109","author":"Haj-Mirzaian","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"24","key":"10.1016\/j.lfs.2023.121803_bb0575","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1523\/JNEUROSCI.22-24-10883.2002","article-title":"Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect","volume":"22","author":"Newton","year":"2002","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0580","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1471-4159.2004.02589.x","article-title":"Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects","volume":"90","author":"Shirayama","year":"2004","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0585","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-010-1844-5","article-title":"Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration","volume":"210","author":"Sperling","year":"2010","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb0595","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcph.286","article-title":"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects","volume":"54","author":"Lowe","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0600","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0605","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.115.229278","article-title":"Receptor occupancy of the kappa-opioid antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050","volume":"356","author":"Naganawa","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0610","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrd.2018.222","article-title":"The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development","volume":"18","author":"Krystal","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0615","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mi.6.3.7","article-title":"The antidepressant -like effects of delta-opioid receptor agonists","volume":"6","author":"Jutkiewicz","year":"2006","journal-title":"Mol. Interv."},{"key":"10.1016\/j.lfs.2023.121803_bb0620","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/164_2017_42","article-title":"Delta opioid receptors and modulation of mood and emotion","volume":"247","author":"Dripps","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb0625","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41386-019-0422-8","article-title":"Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress","volume":"44","author":"Nam","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0630","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0091-3057(95)00067-7","article-title":"Implication of endogenous opioid system in the learned helplessness model of depression","volume":"52","author":"Tejedor-Real","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0635","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-2999(92)90356-9","article-title":"Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation","volume":"216","author":"Baamonde","year":"1992","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb0640","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2022.05.030","article-title":"Contribution of the opioid system to the antidepressant effects of fluoxetine","volume":"92","author":"Carazo-Arias","year":"2022","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0645","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jcpt.12244","article-title":"Delta opioid agonists: a concise update on potential therapeutic applications","volume":"40","author":"Peppin","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb0650","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00008877-200311000-00003","article-title":"Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats","volume":"14","author":"Jutkiewicz","year":"2003","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0655","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2011.04.041","article-title":"The novel delta opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions","volume":"223","author":"Saitoh","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0660","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.brainres.2005.11.005","article-title":"Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats","volume":"1069","author":"Torregrossa","year":"2006","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0665","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1179-y","article-title":"Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats","volume":"164","author":"Broom","year":"2002","journal-title":"Psychopharmacology"},{"issue":"44","key":"10.1016\/j.lfs.2023.121803_bb0670","doi-asserted-by":"crossref","first-page":"27605","DOI":"10.1074\/jbc.272.44.27605","article-title":"Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in xenopus oocytes","volume":"272","author":"Kovoor","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.lfs.2023.121803_bb0675","doi-asserted-by":"crossref","first-page":"15729","DOI":"10.1074\/jbc.M200612200","article-title":"mu-Opioid receptors desensitize less rapidly than delta-opioid receptors due to less efficient activation of arrestin","volume":"277","author":"Lowe","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2023.121803_bb0680","series-title":"Proceedings for Annual Meeting of The Japanese Pharmacological Society","article-title":"A selective delta opioid receptor agonist, KNT-127, exerts an antidepressant-like effect and facilitates neuronal excitability in the mouse infralimbic prefrontal cortex via PI3K-mTOR signaling","volume":"vol. 95","author":"Yoshioka","year":"2022"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2023.121803_bb0685","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0006-8993(93)90843-C","article-title":"Ventral mesencephalic delta opioid receptors are involved in modulation of basal mesolimbic dopamine neurotransmission: an anatomical localization study","volume":"622","author":"Devine","year":"1993","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0690","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0306-4522(91)90106-X","article-title":"Effects of local delta and mu opioid receptor activation on basal and stimulated dopamine release in striatum and nucleus accumbens of rat: an in vivo electrochemical study","volume":"45","author":"Pentney","year":"1991","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0695","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ana.410410311","article-title":"Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography","volume":"41","author":"Madar","year":"1997","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(98)00423-3","article-title":"Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model","volume":"354","author":"Tejedor-Real","year":"1998","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb0705","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/13543776.2013.804066","article-title":"Non-peptidic delta opioid receptor agonists and antagonists (2000\u20132012)","volume":"23","author":"Fujii","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0710","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0893-133X(01)00413-4","article-title":"Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats","volume":"26","author":"Broom","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2023.121803_bb0715","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brainres.2007.07.095","article-title":"Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model","volume":"1208","author":"Saitoh","year":"2008","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0720","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1254\/jphs.FPJ04014X","article-title":"Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents","volume":"95","author":"Saitoh","year":"2004","journal-title":"J. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0725","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1254\/jphs.08149FP","article-title":"Gene expression profiling reveals complex changes in the olfactory bulbectomy model of depression after chronic treatment with antidepressants","volume":"108","author":"Takahashi","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2023.121803_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173341","article-title":"Enhanced antidepressant-like effects of a delta opioid receptor agonist, SNC80, in rats under inflammatory pain","volume":"214","author":"Chen","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0735","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1124\/jpet.111.179432","article-title":"Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor","volume":"338","author":"Hudzik","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2023.121803_bb0740","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pbb.2014.05.009","article-title":"Effects of the delta opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse","volume":"124","author":"Hudzik","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0745","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","article-title":"A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression","volume":"233","author":"Richards","year":"2016","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0750","first-page":"888","article-title":"Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice","volume":"267","author":"Comer","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"23","key":"10.1016\/j.lfs.2023.121803_bb0755","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1111\/bph.12852","article-title":"In vivo properties of KNT-127, a novel delta opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice","volume":"171","author":"Nozaki","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.121803_bb0760","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2007.03.031","article-title":"NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action","volume":"566","author":"Naidu","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0765","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)80235-1","article-title":"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization","volume":"341","author":"Mollereau","year":"1994","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0770","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pharmthera.2013.05.008","article-title":"Nociceptin\/orphanin FQ receptor antagonists as innovative antidepressant drugs","volume":"140","author":"Gavioli","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.lfs.2023.121803_bb0775","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2174\/156802608786264227","article-title":"The ORL-1 receptor system: are there opportunities for antagonists in pain therapy?","volume":"8","author":"Fioravanti","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0780","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1471-4159.1999.0730179.x","article-title":"Orphanin FQ\/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis","volume":"73","author":"Murphy","year":"1999","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0785","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0306-4522(96)00338-7","article-title":"Orphanin FQ is a functional anti-opioid peptide","volume":"75","author":"Mogil","year":"1996","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0790","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/138945007779315605","article-title":"Nociceptin\/orphanin FQ peptide receptors: pharmacology and clinical implications","volume":"8","author":"Chiou","year":"2007","journal-title":"Curr. Drug Targets"},{"issue":"16","key":"10.1016\/j.lfs.2023.121803_bb0795","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1097\/00001756-199711100-00003","article-title":"Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ","volume":"8","author":"Morgan","year":"1997","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0800","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0896-6273(00)81183-6","article-title":"A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ\/nociceptin","volume":"26","author":"Pan","year":"2000","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0805","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.npep.2011.03.002","article-title":"The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction","volume":"45","author":"Mika","year":"2011","journal-title":"Neuropeptides"},{"issue":"14","key":"10.1016\/j.lfs.2023.121803_bb0810","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1111\/bph.13150","article-title":"Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin\/orphanin FQ in mice and monkeys","volume":"172","author":"Rizzi","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.121803_bb0815","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.regpep.2008.06.001","article-title":"Involvement of ORL1 receptor and ERK kinase in the orphanin FQ-induced nociception in the nucleus accumbens of rats","volume":"151","author":"Chen","year":"2008","journal-title":"Regul. Pept."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb0820","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000065432","article-title":"The ORL1 receptor: molecular pharmacology and signalling mechanisms","volume":"11","author":"New","year":"2002","journal-title":"Neurosignals"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0825","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0031-6997(24)01502-3","article-title":"The molecular and behavioral pharmacology of the orphanin FQ\/nociceptin peptide and receptor family","volume":"53","author":"Mogil","year":"2001","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0830","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/pr.114.009209","article-title":"Nociceptin\/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems","volume":"68","author":"Toll","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0835","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrn2647","article-title":"Neural regulation of endocrine and autonomic stress responses","volume":"10","author":"Ulrich-Lai","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0840","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-009-1646-9","article-title":"Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N\/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats","volume":"207","author":"Vitale","year":"2009","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb0845","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00213-018-5004-7","article-title":"NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine","volume":"235","author":"Holanda","year":"2018","journal-title":"Psychopharmacology"},{"issue":"13","key":"10.1016\/j.lfs.2023.121803_bb0850","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00213-016-4310-1","article-title":"Antidepressant activity of nociceptin\/orphanin FQ receptor antagonists in the mouse learned helplessness","volume":"233","author":"Holanda","year":"2016","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0855","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4196\/kjpp.2019.23.6.427","article-title":"Role of nociceptin\/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists","volume":"23","author":"Park","year":"2019","journal-title":"Korean J. Physiol. Pharmacol."},{"issue":"23","key":"10.1016\/j.lfs.2023.121803_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312956","article-title":"Role of nociceptin\/orphanin FQ-NOP receptor system in the regulation of stress-related disorders","volume":"22","author":"Ubaldi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(96)00322-3","article-title":"Intracerebroventricular orphanin FQ\/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats","volume":"75","author":"Murphy","year":"1996","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0870","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cell.2019.06.034","article-title":"A paranigral VTA nociceptin circuit that constrains motivation for reward","volume":"178","author":"Parker","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0875","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00210-004-0939-0","article-title":"Antidepressant-like effects of the nociceptin\/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice","volume":"369","author":"Gavioli","year":"2004","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.lfs.2023.121803_bb0880","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neuint.2009.01.004","article-title":"Inhibition of serotonin outflow by nociceptin\/orphaninFQ in dorsal raphe nucleus slices from normal and stressed rats: role of corticotropin releasing factor","volume":"54","author":"Nazzaro","year":"2009","journal-title":"Neurochem. Int."},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0885","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1476-5381.1996.tb15329.x","article-title":"Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones","volume":"117","author":"Vaughan","year":"1996","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0890","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1476-5381.1996.tb16080.x","article-title":"Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro","volume":"119","author":"Connor","year":"1996","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2023.121803_bb0895","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2003.11.061","article-title":"Tonic inhibition by orphanin FQ\/nociceptin of noradrenaline neurotransmission in the amygdala","volume":"485","author":"Kawahara","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0900","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(01)01721-9","article-title":"Effects of nociceptinNH2 and [Nphe1]nociceptin(1-13)NH2 on rat brain noradrenaline release in vivo and in vitro","volume":"303","author":"Okawa","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0905","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuint.2012.12.011","article-title":"Concurrent modulation of extracellular levels of noradrenaline and cAMP during stress and by anxiogenic- or anxiolytic-like neuropeptides in the prefrontal cortex of awake rats","volume":"62","author":"Yoshitake","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.lfs.2023.121803_bb0910","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroimage.2013.10.068","article-title":"Retest imaging of [11C]NOP-1A binding to nociceptin\/orphanin FQ peptide (NOP) receptors in the brain of healthy humans","volume":"87","author":"Lohith","year":"2014","journal-title":"Neuroimage"},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb0915","first-page":"727","article-title":"Changes and significance of orphanin and serotonin in patients with postpartum depression","volume":"38","author":"Gu","year":"2003","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"13","key":"10.1016\/j.lfs.2023.121803_bb0920","first-page":"916","article-title":"Plasma levels of nociceptin\/orphanin FQ in patients with bipolar disorders and health adults","volume":"89","author":"Wang","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0925","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1176\/appi.ajp.2019.18081007","article-title":"Nociceptin receptors upregulated in cocaine use disorder: a positron emission tomography imaging study using [(11)C]NOP-1A","volume":"176","author":"Narendran","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0930","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/jm500117r","article-title":"Discovery of a novel series of orally active nociceptin\/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7\u2032-thieno[2,3-c]pyran) scaffold","volume":"57","author":"Toledo","year":"2014","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb0935","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/npp.2015.348","article-title":"A selective Nociceptin receptor antagonist to treat depression: evidence from preclinical and clinical studies","volume":"41","author":"Post","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb0940","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.275","article-title":"Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors","volume":"4","author":"Witkin","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb0945","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1124\/dmd.116.070359","article-title":"Occupancy of nociceptin\/orphanin FQ peptide receptors by the antagonist LY2940094 in rats and healthy human subjects","volume":"44","author":"Raddad","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb0950","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/0269881115586937","article-title":"Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice","volume":"29","author":"Almatroudi","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb0955","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effects of opioids: action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb0960","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb0965","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","article-title":"Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy","volume":"28","author":"Nyhuis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb0970","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb0975","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2023.121803_bb0980","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","article-title":"A role for the mu opioid receptor in the antidepressant effects of buprenorphine","volume":"319","author":"Robinson","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2023.121803_bb0985","first-page":"2","article-title":"Buprenorphine as a treatment for major depression and opioid use disorder","author":"Namchuk","year":"2022","journal-title":"Advances Drug Alcohol Res."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb0990","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb0995","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5498\/wjp.v5.i3.330","article-title":"Pharmacologic approaches to treatment resistant depression: evidences and personal experience","volume":"5","author":"Tundo","year":"2015","journal-title":"World J. Psychiatry"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1000","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1254\/jphs.10136SC","article-title":"Antidepressant-like effect of venlafaxine is abolished in mu-opioid receptor-knockout mice","volume":"114","author":"Ide","year":"2010","journal-title":"J. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-2999(82)90241-2","article-title":"Naloxone inhibits clomipramine in mouse forced swimming test","volume":"78","author":"Devoize","year":"1982","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1124\/jpet.109.159939","article-title":"Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes","volume":"332","author":"Onali","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/pr.56.3.2","article-title":"Opioids as modulators of cell death and survival\u2014unraveling mechanisms and revealing new indications","volume":"56","author":"Tegeder","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00023210-200115030-00006","article-title":"Tianeptine: a review of its use in depressive disorders","volume":"15","author":"Wagstaff","year":"2001","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb1025","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"10.1016\/j.lfs.2023.121803_bb1030","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2017.60","article-title":"The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor","volume":"42","author":"Samuels","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb1035","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41386-021-01192-2","article-title":"Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine","volume":"47","author":"Han","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb1040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e3182217a50","article-title":"Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers","volume":"31","author":"Bernard","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-079X.2005.00233.x","article-title":"The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors","volume":"39","author":"Sumaya","year":"2005","journal-title":"J. Pineal Res."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1050","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12671","article-title":"Nociceptive responses in melatonin MT(2) receptor knockout mice compared to MT(1) and double MT(1) \/MT(2) receptor knockout mice","volume":"69","author":"Posa","year":"2020","journal-title":"J. Pineal Res."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb1055","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12825","article-title":"Supraspinal melatonin MT(2) receptor agonism alleviates pain via a neural circuit that recruits mu opioid receptors","volume":"73","author":"Posa","year":"2022","journal-title":"J. Pineal Res."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1060","first-page":"521","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists","volume":"43","author":"Cohen","year":"2018","journal-title":"Reg. Anesth. Pain Med."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1065","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.lfs.2023.121803_bb1070","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.lfs.2023.121803_bb1075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb1080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1085","article-title":"Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults","author":"McCloud","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1090","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","author":"Caddy","year":"2015","journal-title":"The Cochrane database of systematic reviews."},{"key":"10.1016\/j.lfs.2023.121803_bb1095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fpsyt.2014.00149","article-title":"Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation","volume":"5","author":"Morgan","year":"2014","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1100","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","article-title":"The role of ketamine in treatment-resistant depression: a systematic review","volume":"12","author":"Serafini","year":"2014","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1110","first-page":"10","article-title":"Ketamine: review of its pharmacology and its use in pediatric anesthesia","volume":"46","author":"Bergman","year":"1999","journal-title":"Anesth. Prog."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/npp.2014.261","article-title":"Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?","volume":"40","author":"Sanacora","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb1120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2014.04.014","article-title":"Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity","volume":"76","author":"Belujon","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb1125","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00213-013-3378-0","volume":"231","author":"Fukumoto","year":"2014","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of mu-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0091-3057(02)00961-9","article-title":"Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain","volume":"74","author":"Baker","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb1140","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/00000539-200112000-00031","article-title":"The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception","volume":"93","author":"Sarton","year":"2001","journal-title":"Anesth. Analg."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00000542-200307000-00025","article-title":"Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans","volume":"99","author":"Koppert","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.lfs.2023.121803_bb1150","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid receptors","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb1155","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/ALN.0b013e31826a0db3","article-title":"Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers","volume":"117","author":"Niesters","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.lfs.2023.121803_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb1165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000542-198204000-00011","article-title":"Opiate receptor mediation of ketamine analgesia","volume":"56","author":"Finck","year":"1982","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0304-3959(85)90089-2","article-title":"Ketamine analgesia is not related to an opiate action in the periaqueductal gray region of the rat brain","volume":"21","author":"Smith","year":"1985","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1175","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb1180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1476-5381.2009.00310.x","article-title":"Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor","volume":"158","author":"Pacheco Dda","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1190","first-page":"383","article-title":"A novel phencyclidine analog interacts selectively with mu opioid receptors","volume":"230","author":"Itzhak","year":"1984","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.lfs.2023.121803_bb1195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/(SICI)1096-9861(19990614)408:4<549::AID-CNE8>3.0.CO;2-3","article-title":"Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons","volume":"408","author":"Commons","year":"1999","journal-title":"J. Comp. Neurol."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1200","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/npp.2011.155","article-title":"The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control","volume":"37","author":"Rodriguez-Munoz","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2023.121803_bb1205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fphar.2014.00116","article-title":"It\u2019s MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system","volume":"5","author":"Chartoff","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb1210","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv108","article-title":"Methadone reverses analgesic tolerance induced by morphine pretreatment","volume":"19","author":"Posa","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb1215","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1220","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2023.121803_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","author":"Zhang","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.lfs.2023.121803_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1240","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3892\/mmr.2015.3161","article-title":"Phosphatidylethanolamine-binding protein is not involved in micro-opioid receptor-mediated regulation of extracellular signal-regulated kinase","volume":"11","author":"Bian","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1245","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/mol.107.039842","article-title":"Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation","volume":"73","author":"Zheng","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1250","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/00000542-199711000-00016","article-title":"Opioid effects on mitogen-activated protein kinase signaling cascades","volume":"87","author":"Gutstein","year":"1997","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.lfs.2023.121803_bb1255","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/aps.2016.5","article-title":"Ketamine use in current clinical practice","volume":"37","author":"Gao","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1260","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2023.121803_bb1270","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1275","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb1285","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb1290","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1295","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.ajp.2014.13101434","article-title":"A word to the wise about ketamine","volume":"171","author":"Schatzberg","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1300","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pharmrev.120.000149","article-title":"Hydroxynorketamines: pharmacology and potential therapeutic applications","volume":"73","author":"Highland","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1305","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"7604","key":"10.1016\/j.lfs.2023.121803_bb1310","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.lfs.2023.121803_bb1315","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1320","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.lfs.2023.121803_bb1325","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1176\/appi.ajp.2018.18070800","article-title":"Is there really nothing New under the sun? Is low-dose ketamine a fast-acting antidepressant simply because it is an opioid?","volume":"175","author":"George","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269881118812095","article-title":"Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine","volume":"33","author":"Highland","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.lfs.2023.121803_bb1335","doi-asserted-by":"crossref","unstructured":"Kow LM, Commons KG, Ogawa S, Pfaff DW. Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO. Brain Res. 2002;935(1\u20132):87\u2013102.","DOI":"10.1016\/S0006-8993(02)02532-5"},{"issue":"1","key":"10.1016\/j.lfs.2023.121803_bb1340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1523\/JNEUROSCI.17-01-00011.1997","article-title":"mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons","volume":"17","author":"Martin","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2023.121803_bb1345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112631","article-title":"Ketamine\u2019s dose related multiple mechanisms of actions: dissociative anesthetic to rapid antidepressant","volume":"390","author":"Lavender","year":"2020","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1350","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.lfs.2023.121803_bb1355","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/h0043220","article-title":"A continuous performance test of brain damage","volume":"20","author":"Beck","year":"1956","journal-title":"J. Consult. Psychol."},{"issue":"3","key":"10.1016\/j.lfs.2023.121803_bb1360","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1124\/jpet.103.059394","article-title":"Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations","volume":"308","author":"Chavkin","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3\u20134","key":"10.1016\/j.lfs.2023.121803_bb1365","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00213-002-1154-7","article-title":"The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry","volume":"163","author":"Robbins","year":"2002","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1370","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/acschemneuro.0c00741","article-title":"Ketamine metabolite (2R,6R)-hydroxynorketamine interacts with mu and kappa opioid receptors","volume":"12","author":"Joseph","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.lfs.2023.121803_bb1375","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/bbrc.1996.0235","article-title":"delta Opioid receptor in neuronal cells undergoes acute and homologous desensitization","volume":"219","author":"Cai","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1\u20134","key":"10.1016\/j.lfs.2023.121803_bb1380","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0169-328X(94)90044-2","article-title":"Presence of N-methyl-D-aspartate (NMDA) receptors in neuroblastoma x glioma hybrid NG108-15 cells-analysis using [45Ca2+]influx and [3H]MK-801 binding as functional measures","volume":"22","author":"Ohkuma","year":"1994","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.lfs.2023.121803_bb1385","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.neubiorev.2021.10.037","article-title":"Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders","volume":"132","author":"Salaciak","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.lfs.2023.121803_bb1390","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.925879","article-title":"Sigma-1 receptors in depression: mechanism and therapeutic development","volume":"13","author":"Ren","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2023.121803_bb1395","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/jm00061a009","article-title":"Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-binding sites","volume":"36","author":"He","year":"1993","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.lfs.2023.121803_bb1400","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: a literature review","volume":"163","author":"Bair","year":"2003","journal-title":"Arch. Intern. Med."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052300437X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052300437X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:37:32Z","timestamp":1736365052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052300437X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":279,"alternative-id":["S002432052300437X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.121803","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.121803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"121803"}}